Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

Phase 3 Terminated 39 enrolled Alliance for Clinical Trials in Oncology National Cancer Institute (NCI) · collab

RandomizedParallel-groupQuadruple-blindSupportive care

Summary

This phase III trial studies how well dexamethasone works in reducing everolimus-induced oral stomatitis in patients with cancer. Dexamethasone may help to reduce the everolimus-induced oral stomatitis so as to improve quality of life in cancer patients.

Timeline

Start: 2019-06-03
Primary completion: 2021-01-08
Completion: 2022-08-03

Publications

Ruddy KJ, Zahrieh D, He J, Waechter B, Holleran JL, Lewis LD, Chow S, Beumer J, Weiss M, Trikalinos N, Faller B, Lustberg M, Rugo HS, Loprinzi C. Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). Semin Oncol. 2023 Feb-Apr;50(1-2):7-10. doi: 10.1053/j.seminoncol.2023.01.001. Epub 2023 Jan 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dexamethasone	Small molecule	10 ml	Oral
Subject	Everolimus	Small molecule	10 mg	Oral

Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer

Summary

Timeline

Publications

Drugs

Indications